Colorado BioScience Association Announces 2010 Sponsors and Appoints Nine New Board Members
Summary
Denver, CO, April 21, 2010 --( The CBSA’s 2010 association sponsors include: Titanium – Fitzsimons Life Science District, fitzscience.com Platinum – University of Colorado, cu.edu - Colorado State University, colostate.edu Gold – Merck, merck.com - Snell & Wilmer, swlaw.com - Boettcher Foundation, boettcherfoundation.org Silver – Amgen, amgen.com - CaridianBCT, caridianbct.com - Cooley Godward Kronish, cooley.com - Pfizer, pfizer.com - Ernst & Young, ey.com Bronze – Fairfield and Woods, fwlaw.com - OSI Pharmaceuticals, osip.com - Hogan and Hartson, hhlaw.com - Baxa, baxa.com - PhRMA, phrma.org - Polsinelli Shughart, polsinelli.com - We Work for Health, weworkforhealth.org - Dorsey & Whitney, dorsey.com - TriNet, trinet.com Joining Jory on the CBSA Board officer team will be newly appointed vice chairperson Steve Orndorff, President & CEO, Accera, http://www.accerapharma.com.Newly appointed CBSA board members include: Denise Brown, Principal, DM Brown LLC (presently serving as CBSA Interim Executive Director) Betty Iverson, State Government Affairs, Johnson & Johnson, jnj.com Ruth Lytle-Barnaby, Executive Director, Poudre Valley Health System Foundation, pvhs.org Nick Saccamono, Chief Technology Officer, SomaLogic, somalogic.com Chris Smith, President, Cochlear, cochlear.com Will Vaughn, Director of Technology Transfer, Colorado School of Mines, mines.edu Jim Wilson, Senior Audit Manager, Ernst & Young, ey.com Dan Wittenberg, Partner, Snell & Wilmer, swlaw.com Michael Weiner, Partner, Dorsey & Whitney, dorsey.com Nominations for new board members were taken from the CBSA membership and acted upon by the 2010 Nominating Committee.The CBSA Board of Directors is comprised of members from the following business affiliations: * 20% from traditional biotechnology companies * 20% from traditional medical device companies * 10% from research organizations * 10% from service providers * 10% from emerging companies * Remainder based on need and opportunity Reappointed board members, approved by the membership, include: Rick Duke, President & CEO, CID4, cid4.com and Apoplogic, apoplogic.com Derek Cole, Vice President Investor Relations & Corporate Communications, ARCA Biopharma, arcabiopharma.com Kevin Smith, Executive Vice President & COO, CID4, cid4.com Dave Allen, Associate Vice President for Technology Transfer, University of Colorado, colorado.edu Michael Salem, President & CEO, National Jewish Health, nationaljewish.org David Perez, President & CEO, CaridianBCT, caridianbct.com Linda Pryor, Director of Government Relations and Public Affairs, Pfizer, pfizer.com Harry Ross, Managing Partner, Aweida Ventures, aweida.com Sean Moriarty, VP General Counsel, Tolmar, tolmar.com Rahmat Shoureshi, Dean School of Engineering and Computer Science, University of Denver, du.edu In addition to association business, attendees at the CBSA’s Annual All-Member Meeting also enjoyed industry networking and presentations about the Colorado Institute for Drug, Device and Diagnostic Development (CID4) by Rick Duke and Kevin Smith, and the Colorado Center for Drug Discovery (C2D2) by Terry Opgenorth.Jory, CEO of Sandhill Scientific, Inc. - http://www.sandhillsci.com - Highlands Ranch, is beginning his second year of a two-year term as Chairperson.The CBSA’s 2010 association sponsors include:Titanium – Fitzsimons Life Science District, fitzscience.comPlatinum – University of Colorado, cu.edu - Colorado State University, colostate.eduGold – Merck, merck.com - Snell & Wilmer, swlaw.com - Boettcher Foundation, boettcherfoundation.orgSilver – Amgen, amgen.com - CaridianBCT, caridianbct.com - Cooley Godward Kronish, cooley.com - Pfizer, pfizer.com - Ernst & Young, ey.comBronze – Fairfield and Woods, fwlaw.com - OSI Pharmaceuticals, osip.com - Hogan and Hartson, hhlaw.com - Baxa, baxa.com - PhRMA, phrma.org - Polsinelli Shughart, polsinelli.com - We Work for Health, weworkforhealth.org - Dorsey & Whitney, dorsey.com - TriNet, trinet.comJoining Jory on the CBSA Board officer team will be newly appointed vice chairperson Steve Orndorff, President & CEO, Accera, http://www.accerapharma.com.The CBSA Board of Directors is comprised of members from the following business affiliations:* 20% from traditional biotechnology companies* 20% from traditional medical device companies* 10% from research organizations* 10% from service providers* 10% from emerging companies* Remainder based on need and opportunityReappointed board members, approved by the membership, include:Rick Duke, President & CEO, CID4, cid4.com and Apoplogic, apoplogic.comDerek Cole, Vice President Investor Relations & Corporate Communications, ARCA Biopharma, arcabiopharma.comKevin Smith, Executive Vice President & COO, CID4, cid4.comDave Allen, Associate Vice President for Technology Transfer, University of Colorado, colorado.eduMichael Salem, President & CEO, National Jewish Health, nationaljewish.orgDavid Perez, President & CEO, CaridianBCT, caridianbct.comLinda Pryor, Director of Government Relations and Public Affairs, Pfizer, pfizer.comHarry Ross, Managing Partner, Aweida Ventures, aweida.comSean Moriarty, VP General Counsel, Tolmar, tolmar.comRahmat Shoureshi, Dean School of Engineering and Computer Science, University of Denver, du.eduIn addition to association business, attendees at the CBSA’s Annual All-Member Meeting also enjoyed industry networking and presentations about the Colorado Institute for Drug, Device and Diagnostic Development (CID4) by Rick Duke and Kevin Smith, and the Colorado Center for Drug Discovery (C2D2) by Terry Opgenorth.About Colorado BioScience AssociationThe Colorado BioScience Association (CBSA) supports the economic development of Colorado through the creation of a premier bioscience cluster within the state.
Classifications
AskAI Classifications
LabelsLinked Companies
